110 related articles for article (PubMed ID: 2032225)
1. Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells.
Cho YL; Christensen C; Saunders DE; Lawrence WD; Deppe G; Malviya VK; Malone JM
Cancer Res; 1991 Jun; 51(11):2848-53. PubMed ID: 2032225
[TBL] [Abstract][Full Text] [Related]
2. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines.
Moffatt KA; Johannes WU; Miller GJ
Clin Cancer Res; 1999 Mar; 5(3):695-703. PubMed ID: 10100724
[TBL] [Abstract][Full Text] [Related]
3. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
Swami S; Krishnan AV; Feldman D
Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
[TBL] [Abstract][Full Text] [Related]
4. 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage.
Ravid A; Rocker D; Machlenkin A; Rotem C; Hochman A; Kessler-Icekson G; Liberman UA; Koren R
Cancer Res; 1999 Feb; 59(4):862-7. PubMed ID: 10029076
[TBL] [Abstract][Full Text] [Related]
5. Regulation of epidermal growth factor receptor levels by 1,25-dihydroxyvitamin D3 in human breast cancer cells.
Koga M; Eisman JA; Sutherland RL
Cancer Res; 1988 May; 48(10):2734-9. PubMed ID: 2834048
[TBL] [Abstract][Full Text] [Related]
6. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668
[TBL] [Abstract][Full Text] [Related]
7. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
8. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
Tyagi AK; Agarwal C; Chan DC; Agarwal R
Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
[TBL] [Abstract][Full Text] [Related]
9. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
10. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
Chang MJ; Yu WD; Reyno LM; Modzelewski RA; Egorin MJ; Erkmen K; Vlock DR; Furmanski P; Johnson CS
Cancer Res; 1994 Oct; 54(20):5380-6. PubMed ID: 7923169
[TBL] [Abstract][Full Text] [Related]
11. Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines.
Wigington DP; Urben CM; Strugnell SA; Knutson JC
Anticancer Res; 2004; 24(5A):2905-12. PubMed ID: 15517895
[TBL] [Abstract][Full Text] [Related]
12. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP
Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697
[TBL] [Abstract][Full Text] [Related]
13. Amphiregulin is a vitamin D3 target gene in squamous cell and breast carcinoma.
Akutsu N; Bastien Y; Lin R; Mader S; White JH
Biochem Biophys Res Commun; 2001 Mar; 281(4):1051-6. PubMed ID: 11237771
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D analogs: new therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia.
Yu J; Papavasiliou V; Rhim J; Goltzman D; Kremer R
Anticancer Drugs; 1995 Feb; 6(1):101-8. PubMed ID: 7756673
[TBL] [Abstract][Full Text] [Related]
15. The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth.
Gavrilov V; Steiner M; Shany S
Anticancer Res; 2005; 25(5):3425-9. PubMed ID: 16101159
[TBL] [Abstract][Full Text] [Related]
16. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.
Barreto AM; Schwartz GG; Woodruff R; Cramer SD
Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):265-70. PubMed ID: 10750664
[TBL] [Abstract][Full Text] [Related]
17. The novel analog 1,24(S)-dihydroxyvitamin D2 is as equipotent as 1,25-dihydroxyvitamin D3 in growth regulation of cancer cell lines.
Levy Y; Knutson JC; Bishop C; Shany S
Anticancer Res; 1998; 18(3A):1769-75. PubMed ID: 9673403
[TBL] [Abstract][Full Text] [Related]
18. 1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death.
Wang Q; Yang W; Uytingco MS; Christakos S; Wieder R
Cancer Res; 2000 Apr; 60(7):2040-8. PubMed ID: 10766196
[TBL] [Abstract][Full Text] [Related]
19. 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells.
Hisatake J; Kubota T; Hisatake Y; Uskokovic M; Tomoyasu S; Koeffler HP
Cancer Res; 1999 Aug; 59(16):4023-9. PubMed ID: 10463602
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response.
Blommaert FA; Michael C; Terheggen PM; Muggia FM; Kortes V; Schornagel JH; Hart AA; den Engelse L
Cancer Res; 1993 Dec; 53(23):5669-75. PubMed ID: 8242622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
